PURPOSE: During the last 25 years, National Cancer Institute (NCI) cooperative trial groups have extended trial networks from academic centers to include certain community and Veterans Health Administration (VHA) centers. We compared trial patients' attributes and outcomes by these enrollment settings. PATIENTS AND METHODS: Studying 2,708 patients on one of 10 cooperative group, randomized lung trials at 272 institutions, we compared patient attributes by enrollment setting (ie, academic, community, and VHA affiliates). We used adjusted Cox regression to evaluate for survival differences by setting. RESULTS: Main member institutions enrolled 44% of patients; community affiliates enrolled 44%; and VHAs enrolled 12%. Patient attributes (ie, case-mix) of age, ethnicity, sex, and performance status varied by enrollment setting. After analysis was adjusted for patient case-mix, no mortality differences by enrollment setting were noted. CONCLUSION: Although trial patients with primarily advanced-stage lung cancer from nonacademic centers were older and had worse performance statuses than those from academic centers, survival did not differ by enrollment setting after analysis accounted for patient heterogeneity. An answer for whether long-term outcomes for patients at community and VHA centers affiliated with cooperative trial groups are equivalent to those at academic centers when care is delivered through NCI trials requires additional research among patients with longer survival horizons.
PURPOSE: During the last 25 years, National Cancer Institute (NCI) cooperative trial groups have extended trial networks from academic centers to include certain community and Veterans Health Administration (VHA) centers. We compared trial patients' attributes and outcomes by these enrollment settings. PATIENTS AND METHODS: Studying 2,708 patients on one of 10 cooperative group, randomized lung trials at 272 institutions, we compared patient attributes by enrollment setting (ie, academic, community, and VHA affiliates). We used adjusted Cox regression to evaluate for survival differences by setting. RESULTS: Main member institutions enrolled 44% of patients; community affiliates enrolled 44%; and VHAs enrolled 12%. Patient attributes (ie, case-mix) of age, ethnicity, sex, and performance status varied by enrollment setting. After analysis was adjusted for patient case-mix, no mortality differences by enrollment setting were noted. CONCLUSION: Although trial patients with primarily advanced-stage lung cancer from nonacademic centers were older and had worse performance statuses than those from academic centers, survival did not differ by enrollment setting after analysis accounted for patient heterogeneity. An answer for whether long-term outcomes for patients at community and VHA centers affiliated with cooperative trial groups are equivalent to those at academic centers when care is delivered through NCI trials requires additional research among patients with longer survival horizons.
Authors: Linda S Elting; Catherine Cooksley; B Nebiyou Bekele; Michael Frumovitz; Elenir B C Avritscher; Charlotte Sun; Diane C Bodurka Journal: Cancer Date: 2006-06-01 Impact factor: 6.860
Authors: Everett E Vokes; James E Herndon; Michael J Kelley; M Giulia Cicchetti; Nithya Ramnath; Harvey Neill; James N Atkins; Dorothy M Watson; Wallace Akerley; Mark R Green Journal: J Clin Oncol Date: 2007-04-02 Impact factor: 44.544
Authors: Edward F McClay; Jeff Bogart; James E Herndon; Dee Watson; Lisa Evans; Steven L Seagren; Mark R Green Journal: Am J Clin Oncol Date: 2005-02 Impact factor: 2.339
Authors: Warren B Sateren; Edward L Trimble; Jeffrey Abrams; Otis Brawley; Nancy Breen; Leslie Ford; Mary McCabe; Richard Kaplan; Malcolm Smith; Richard Ungerleider; Michaele C Christian Journal: J Clin Oncol Date: 2002-04-15 Impact factor: 44.544
Authors: M P Kosty; S B Fleishman; J E Herndon; K Coughlin; A B Kornblith; A Scalzo; J C Morris; J Mortimer; M R Green Journal: J Clin Oncol Date: 1994-06 Impact factor: 44.544
Authors: L H Maurer; J E Herndon; D R Hollis; J Aisner; R W Carey; A T Skarin; M C Perry; W L Eaton; L L Zacharski; S Hammond; M R Green Journal: J Clin Oncol Date: 1997-11 Impact factor: 44.544
Authors: Vijaya Raj Bhatt; Prajwal Dhakal; Sumit Dahal; Smith Giri; Ranjan Pathak; R Gregory Bociek; Peter T Silberstein; James O Armitage Journal: Ther Adv Hematol Date: 2015-10
Authors: Mary Beth Landrum; Nancy L Keating; Elizabeth B Lamont; Samuel R Bozeman; Steven H Krasnow; Lawrence Shulman; Jennifer R Brown; Craig C Earle; Michael Rabin; Barbara J McNeil Journal: J Clin Oncol Date: 2012-03-05 Impact factor: 44.544
Authors: Bree R Eaton; Stephanie L Pugh; Jeffrey D Bradley; Greg Masters; Vivek S Kavadi; Samir Narayan; Lucien Nedzi; Cliff Robinson; Raymond B Wynn; Christopher Koprowski; Douglas W Johnson; Joanne Meng; Walter J Curran Journal: J Natl Cancer Inst Date: 2016-05-19 Impact factor: 13.506
Authors: Carolyn J Presley; Daiwei Tang; Pamela R Soulos; Anne C Chiang; Janina A Longtine; Kerin B Adelson; Roy S Herbst; Weiwei Zhu; Nathan C Nussbaum; Rachael A Sorg; Vineeta Agarwala; Amy P Abernethy; Cary P Gross Journal: JAMA Date: 2018-08-07 Impact factor: 56.272
Authors: Eliza M Park; Elise M Stephenson; Cynthia W Moore; Allison M Deal; Anna C Muriel Journal: Support Care Cancer Date: 2018-10-27 Impact factor: 3.603
Authors: Inna Y Gong; Andrew T Yan; Craig C Earle; Maureen E Trudeau; Andrea Eisen; Kelvin K W Chan Journal: Breast Cancer Res Treat Date: 2020-03-31 Impact factor: 4.872
Authors: Janice H Jou; Mark S Sulkowski; Stephanie Noviello; Jianmin Long; Lisa D Pedicone; John G McHutchison; Andrew J Muir Journal: J Clin Gastroenterol Date: 2013 Nov-Dec Impact factor: 3.062